

Osteoporosis Screening in Older Women (OSW)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for osteoporosis screening in older women (OSW).

What Is the Measure?

The percentage of women ages 65-75 years who received osteoporosis screening

Exclusions

- Persons who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Persons who die any time during the measurement year.
- Persons receiving palliative care any time during the measurement year.
- Persons who had an encounter for palliative care any time during the measurement year. Do not include laboratory claims.
- Persons ages 66 years and older as of December 31 of the measurement year (all product lines) with frailty **and** advanced illness. Persons must meet **both** frailty and advanced illness criteria to be excluded:
 1. **Frailty.** At least two indications of frailty with different dates of service during the measurement year.
 2. **Advanced Illness.** Any of the following during the measurement year or the year prior to the measurement year:
 - Advanced illness on at least two different dates of service
 - Dispensed dementia medication

Dementia Medications

Description	Prescription
Cholinesterase inhibitors	<ul style="list-style-type: none"> • Donepezil • Galantamine • Rivastigmine
Miscellaneous central nervous system agents	<ul style="list-style-type: none"> • Memantine
Dementia combinations	<ul style="list-style-type: none"> • Donepezil-memantine

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Osteoporosis Medications

Description	Prescription
Bisphosphonates	<ul style="list-style-type: none">• Alendronate• Alendronate-cholecalciferol• Ibandronate• Risedronate• Zoledronic acid
Other agents	<ul style="list-style-type: none">• Abaloparatide• Denosumab• Raloxifene• Romosozumab• Teriparatide

What Meets the Measure Requirements?

One or more osteoporosis screening tests on or between the person's 65th birthday and December 31 of the measurement year.

CPT Code: 76977-77081, 77085

Content reproduced with permission from HEDIS® MY2026, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [NCQA.org/Publications](https://www.ncqa.org/Publications)